Pharmacogenomics can play a role in lowering the cost of health care expenditures, such as shortening hospital stays and reducing emergency department visits.
The relative abundance of gram-negative Bacteroidetes to other phyla, such as gram-positive Firmicutes, is essential to maintain biodiversity and human gut health.
The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.
This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.
The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) introduced changes to streamline its drug approval processes.
Pharmacists have been central to vaccine distribution since the COVID-19 pandemic, and as viruses spread, they must continue urging patients to stay updated on vaccinations to prevent severe illness and reduce hospitalizations.
AI is significantly enhancing the efficiency of identifying and enrolling patients.
Duration of therapy may be just 5 to 6 days for patients without risk factors for complications.
Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.
This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.
Student pharmacists can work toward a better future for patients, themselves, and the profession.
Ochsner Children’s Hospital, in partnership with ISMP, has launched a fellowship to advance pediatric medication safety through hands-on training in key competencies, national safety strategies, interdisciplinary collaboration, and innovative tools such as AI and data dashboards.
For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.
Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.
Hospitals, health systems, and the supply chain are all negatively impacted by drug shortages and are each affected by the decisions of the others.
Digital pharmacy solutions are revolutionizing patient care.
Although pharmacists possess a wealth of knowledge on AEs, it remains a monumental task to recall the clinical significance of every AE, even with the most commonly used medications.
Palliative pharmacists are invaluable assets of oncologic care.
The US health care market faces transformative changes in 2025, as biosimilars, GLP-1s, and new pharmacy economics reshape how benefit managers balance innovation with affordability.
Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.
Integrated health system specialty pharmacies can improve patient care for non–multiple sclerosis neurologic conditions.
Although OTC medications are generally considered safe when used as directed, there are some key drug interactions for pharmacists to keep in mind when helping patients choose an OTC product.
When helping individuals prepare for travel, pharmacists must make travel health recommendations and know common travel-related immunizations and additional resources.
The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.
Manufacturers must find the right balance in drug pricing, so that medications are appealing to both public and private insurers while still remaining profitable throughout their lifecycle.
With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Best practices to train staff and team members to engage patients and to ease the new vaccine offerings into the workflow are also discussed.
Patients with MDD may also seek complementary or alternative therapies in the form of dietary supplements which might be perceived by patients to be natural and safer than medicinal agents.